



**URGENT: DRUG RECALL** 

135 Foute 202, 206, Suite 15 Bedminster, NJ 07921 TEL: (201) 476-1977 FAX: (201) 476-1987 www.thepharmanetwork.com May 23, 2025

Hindy Schiff Vice President Regulatory Affairs and Compliance Ascend Laboratories, LLC 135 US Highway 202-206, Suite 15 Bedminster, NJ, 07921

#### Dear Customer:

This is to inform you of a product recall involving Cephalexin FOS, 125 mg/5 mL. Please reference lot-specific information included below.

	Product Name	Lot Number	Strength	Expiration Date	Pack Size	NDC	Initial Distribution Date	Quantity Distributed (in bottles)
1	Cephalexin FOS, 125 mg/5 mL	23141828	125 mg/ 5mL	May 2025	100 mL	67877- 544-88	September 20, 2023	7,008
2	Cephalexin FOS, 125 mg/5 mL	23141829	125 mg/ 5 mL	May 2025	100 mL	67877- 544-88	October 4, 2023	7,008
3	Cephalexin FOS, 125 mg/5 mL	23142342	125 mg/ 5 mL	June 2025	100 mL	67877- 544-88	October 16, 2023	6,984
4	Cephalexin FOS, 125 mg/5 mL	23142343	125 mg/ 5 mL	June 2025	100 mL	67877- 544-88	September 1, 2023	3,372
5	Cephalexin FOS, 125 mg/5 mL	23142708	125 mg/ 5 mL	July 2025	100 mL	67877- 544-88	November 9, 2023	7,008
6	Cephalexin FOS, 125 mg/5 mL	23143526	125 mg/ 5 mL	September 2025	200 mL	67877- 544-68	December 1, 2023	3,360
7	Cephalexin FOS, 125 mg/5 mL	23144035	125 mg/ 5 mL	October 2025	100 mL	67877- 544-88	May 1, 2024	7,032
8	Cephalexin FOS, 125 mg/5 mL	23144036	125 mg/ 5 mL	October 2025	200 mL	67877- 544-68	February 2, 2024	3,060

9	Cephalexin FOS, 125 mg/5 mL	23144269	125 mg/ 5 mL	November 2025	200 mL	67877- 544-68	September 23, 2024	564
10	Cephalexin FOS, 125 mg/5 mL	23144270	125 mg/ 5 mL	November 2025	100 mL	67877- 544-88	April 25, 2024	7,032
11	Cephalexin FOS, 125 mg/5 mL	24140026	125 mg/ 5 mL	December 2025	100 mL	67877- 544-88	June 7, 2024	6,864
12	Cephalexin FOS, 125 mg/5 mL	24140027	125 mg/ 5 mL	December 2025	200 mL	67877- 544-68	August 28, 2024	252
13	Cephalexin FOS, 125 mg/5 mL	24144282	125 mg/ 5 mL	October 2026	200 mL	67877- 544-68	March 5, 2025	12
			Total	Distributed	1	•		59,556

See enclosed product labels for ease in identifying the product at the WHOLESALE level.

An out-of-specification (OOS) result was observed in the related substance test at the sixth month of stability analysis (with conditions set at 25°C± 2°C/60%±5%RH) of Cephalexin for Oral Suspension USP 125 mg/5 mL. The individual impurity was identified to be Cephalexin Glucose Adduct. As a precautionary measure, all non-expired batches are being recalled from the market.

Cephalexin is used to treat infections caused by bacteria such as pneumonia and other respiratory infections as well as infections of the bones, skin, ears, genitalia, and urinary tract. Cephalexin is considered a cephalosporin and works by killing infection-inducing bacteria. This medicine is only available by prescription and can only be used to treat patients 15 years of age and older. To date, there have been no adverse events reported by patients who have ingested Cephalexin containing the impurity.

Our firm began shipping this product on September 1, 2023. Immediately examine your inventory and quarantine product subject to recall for the lot numbers specified in the table above.

Please perform the following activities:

- a. Immediately examine your inventory and quarantine product subject to recall for the lot numbers specified in the table above. Please follow the directions in the attached recall stock response to return the affected product.
- b. Promptly complete the attached recall stock response form even if you have no product to return.
- c. The completed Recall Response Form can be submitted by any of the following methods:

Fax: 817-868-5362 or E-mail: rxrecalls@inmar.com

This recall is being carried out to the WHOLESALE level. Your assistance is appreciated and necessary to prevent consumer harm.

If you have any questions related to customer service, please contact product inquiries—available 24 hours a day, 7 days a week—at 877-272-7901. If you have any questions about the return of the product, please contact Inmar toll free at 855-243-9132—available 9:00 AM to 5:00 PM ET Monday through Friday.

This recall is being conducted with the knowledge of the Food and Drug Administration.

Sincerely,

Hindy Schiff

Vice President, Regulatory Affairs and Compliance

Ascend Laboratories, LLC

135 US Highway 202-206, Suite 15

Bedminster, NJ, 07921



# PRODUCT IMAGE

### Batch # 24144282








#### Batch # 23144269








### Batch # 23144035









### Batch # 23141828














## Batch # 23141829







# Batch # 23140026



Prepared By Recall Coordinator (Sign & Date)

Nitish K. Pandey Chigitally signed by Nitish K. Prandey
Date: 2025.05.15 11:55:39 + 05'30'

## RECALL STOCK RESPONSE FORM

Recall: Cephalexin FOS, 125 mg/5mL

Lots: 23141828, 23141829, 23142342, 23142343, 23142708, 23143526, 23144035, 23144036, 23144269, 23144270, 24140026, 24140027, 24144282

Customer Name:		DEA #:			
*Please note that DEA # is req	uired. If it is not provided,	the processing of your form will be delayed. *			
Address:					
City:	State:	Zip Code:			
Contact Name (please print):		Telephone #:			
Contact Signature:		Date:			
		Ascend:Wholesaler DEA#: State: Wholesaler Zip:			
Please_check and fill out each		State wholesater zip			
		ons provided in the Recall Letter. ventory indicated in the table below.			

	Product Name	Lot Number	Strength	Expiration Date	Pack Size	NDC	Quantity on Hand (in Bottles)
1	Cephalexin FOS, 125 mg/5 mL	23141828	125 mg/ 5mL	May 2025	100 mL	67877- 544-88	
2	Cephalexin FOS, 125 mg/5 mL	23141829	125 mg/ 5 mL	May 2025	100 mL	67877- 544-88	
3	Cephalexin FOS, 125 mg/5 mL	23142342	125 mg/ 5 mL	June 2025	100 mL	67877- 544-88	
4	Cephalexin FOS, 125 mg/5 mL	23142343	125 mg/ 5 mL	June 2025	100 mL	67877- 544-88	

5	Cephalexin FOS, 125 mg/5 mL	23142708	125 mg/ 5 mL	July 2025	100 mL	67877- 544-88
6	Cephalexin FOS, 125 mg/5 mL	23143526	125 mg/ 5 mL	September 2025	200 mL	67877- 544-68
7	Cephalexin FOS, 125 mg/5 mL	23144035	125 mg/ 5 mL	October 2025	100 mL	67877- 544-88
8	Cephalexin FOS, 125 mg/5 mL	23144036	125 mg/ 5 mL	October 2025	200 mL	67877- 544-68
9	Cephalexin FOS, 125 mg/5 mL	23144269	125 mg/ 5 mL	November 2025	200 mL	67877- 544-68
10	Cephalexin FOS, 125 mg/5 mL	23144270	125 mg/ 5 mL	November 2025	100 mL	67877- 544-88
11	Cephalexin FOS, 125 mg/5 mL	24140026	125 mg/ 5 mL	December 2025	100 mL	67877- 544-88
12	Cephalexin FOS, 125 mg/5 mL	23141828	125 mg/ 5mL	December 2025	200 mL	67877- 544-68
13	Cephalexin FOS, 125 mg/5 mL	23141829	125 mg/ 5 mL	October 2026	200 mL	67877- 544-68
			Total Produ	ıct		

L	indicate	disposition	on of r	ecall	prod	uct:
---	----------	-------------	---------	-------	------	------

)	Returnea/Hela	tor Ke	turn (Yes	/ NO)	
---	---------------	--------	-----------	-------	--

•	Quantity:
	Date:
	Method:

OR

o No recall product on hand (Yes / No)

	I have	identified and notified my customers that this product was shipped/received or may
	have b	een shipped by:
	0	Date:
	0	Method of Notification:
Were	there an	y adverse events associated with the recalled product?
	Yes	
L	No	
If yes,	please (	explain:
If you	have an	y questions regarding this form or product return, please contact Inmar at 1-855-243- 9132. Office Hours: 9:00 AM to 5:00 PM EST Monday through Friday.
	Plea	se return this form by fax to 1-817-868-5362 or E-mail rxrecalls@inmar.com.
Af	ter recei	pt of this response form, a return kit will be provided for affected product return to:
		Inmar Rx Solutions
		3845 Grand Lakes Way
		Grand Prairie, TX, 75050

Inmar Recall Event ID: RCL108-2025